secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001297184-25-000025
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74
------------------------------------------------------------------------

- Net revenues $170.5M, down from $171.8M in Q1 2024.
- GAAP net income $25.3M ($0.51 diluted EPS) vs $43.2M ($0.81) last year.
- Adjusted non-GAAP net income $36.9M ($0.74 EPS) vs $55.3M ($1.04) prior year.
- CEO cites BAQSIMI and Primatene MIST growth; FDA accepted insulin biosimilar AMP-004 application.
- Company managing resources for efficient operations amid revenue decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/0001297184-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/amph-20250507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer